Documento di consenso FCSA, SIMeL, SIBioC e CISMEL sul monitoraggio di laboratorio dei nuovi farmaci anticoagulanti orali

Translated title of the contribution: Consensus document of FCSA, SIMeL, SIBioC e CISMEL on laboratory monitoring of novel oral anticoagulant drugs

Giuseppe Lippi, Giancarlo Di Iorio, Sophie Testa, Cesare Manotti, Armando Tripodi

Research output: Contribution to journalArticlepeer-review

Abstract

Summary Oral anticoagulant therapy (OAT) is used to prevent and treat thromboembolic diseases. The new oral anticoagulants (NOAs) can be prescribed at fixed dosage without adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper represents the consensus document of three Italian scientific societies dealing with laboratory issues in thrombosis and haemostasis. It is aimed at reviewing (i) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available (i.e., dabigatran, rivaroxaban and apixaban); (ii) the patients to be investigated and (iii) the timing of investigation.

Translated title of the contributionConsensus document of FCSA, SIMeL, SIBioC e CISMEL on laboratory monitoring of novel oral anticoagulant drugs
Original languageItalian
Pages (from-to)131-133
Number of pages3
JournalRivista Italiana della Medicina di Laboratorio
Volume9
Issue number3
DOIs
Publication statusPublished - Sep 2013

ASJC Scopus subject areas

  • Biochemistry, medical
  • Medical Laboratory Technology

Fingerprint

Dive into the research topics of 'Consensus document of FCSA, SIMeL, SIBioC e CISMEL on laboratory monitoring of novel oral anticoagulant drugs'. Together they form a unique fingerprint.

Cite this